# Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

> **NCT03483948** · PHASE1 · TERMINATED · sponsor: **Hutchison Medipharma Limited** · enrollment: 7 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** HMPL-523
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03483948
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-09
- **Primary completion:** 2019-09-09
- **Final completion:** 2019-09-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow Enrollment
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03483948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03483948, "Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03483948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*